ICMR Transfers Indigenous Cervical Cancer Drug and Vaccine Technologies to Emcure and Biological E

ICMR transfers indigenous cervical cancer drug and vaccine technologies to Emcure and Biological E

ICMR has licensed a cervical cancer drug candidate to Emcure and two vaccine technologies to Biological E to accelerate affordable healthcare innovations.

India’s Indigenous Cancer and Vaccine Research Enters Next Phase

July 21, 2026: A cancer therapy candidate designed to target HPV-related precancerous lesions and two vaccine technologies against major enteric infections have moved one step closer to further development following technology transfer agreements facilitated by the Indian Council of Medical Research (ICMR). Under its Medical Innovations Patent Mitra initiative, ICMR has licensed three indigenous biomedical technologies to Indian pharmaceutical a…

ICMR licenses three indigenous cancer and vaccine technologies to Indian pharma firms

New Delhi: The Indian Council of Medical Research (ICMR) has licensed three indigenous biomedical technologies to leading domestic pharmaceutical and vaccine makers for development, manufacturing and commercialisation, an official statement said on Tuesday.  These technology transfers mark another significant step towards accelerating the translation of publicly funded research into affordable healthcare solutions and strengthening India's biome…

ICMR transfers three indigenous biomedical technologies to advance cancer and infectious disease solutions

New Delhi, July 21, 2026: The Indian Council of Medical Research (ICMR), under its Medical Innovations Patent Mitra initiative, facilitated the licensing of three indigenous biomedical technologies to leading Indian pharmaceutical and vaccine manufacturers for further development, manufacturing and commercialization. The technologies include SHetA2, a novel anti-HPV therapeutic candidate for the treatment of Cervical Intraepithelial Neoplasia (C…